Article Details

CTI BioPharma Corp (NASDAQ:CTIC) Submits NDA For Its Pacritinib To Treat Myelofibrosis ...

Retrieved on: 2021-04-08 12:11:15

Tags for this article:

Click the tags to see associated articles and topics

CTI BioPharma Corp (NASDAQ:CTIC) Submits NDA For Its Pacritinib To Treat Myelofibrosis .... View article details on hiswai:

Excerpt

CTI BioPharma Corp (NASDAQ:CTIC) submitted NDA (new drug application) for its innovative drug formulation – Pacritinib to the US FDA.

Article found on: biopharmajournal.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up